VSTM Live signals | Maximize Profits with Getagraph.com

BUY 157785 min ago

@ $11.85

Issued: 14 Feb 2024 @ 13:14

Return: -66.58%

Previous signal: Feb 13 - 12:38

Previous signal: Sell

Return: 1.28 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	968 875
Average Volume	570 977
Market Cap	100.29M
EPS	$0 ( 2024-05-14 )
Next earnings date	( $-1.030 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.930
ATR14	$0.0120 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Calkins Daniel	Sell	6	Common Stock
2024-03-25	Calkins Daniel	Sell	25	Common Stock
2024-03-20	Calkins Daniel	Sell	55	Common Stock
2024-03-18	Gagnon Robert E.	Sell	283	Common Stock
2024-03-19	Gagnon Robert E.	Sell	130	Common Stock

INSIDER POWER
49.32
Last 99 transactions
Buy: 1 037 036 \| Sell: 241 539

Volume Correlation

Long: 0.02 (neutral)

Short: -0.07 (neutral)

Signal:(45.665) Neutral

Verastem Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Verastem Inc Correlation - Currency/Commodity

0.27
( neutral )

0.23
( neutral )

0.00
( neutral )

-0.02
( neutral )

-0.15
( neutral )

Verastem Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-62 000.00 (0.00 %)
EPS:	$-3.96

FY	2023
Revenue:	$0
Gross Profit:	$-62 000.00 (0.00 %)
EPS:	$-3.96

FY	2022
Revenue:	$2.60M
Gross Profit:	$2.48M (95.45 %)
EPS:	$-4.58

FY	2021
Revenue:	$2.05M
Gross Profit:	$2.05M (100.00 %)
EPS:	$-0.464

Financial Reports:

No articles found.

Verastem Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Verastem Inc

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.